2022
A Pilot randomized trial to examine effects of a hybrid closed-loop insulin delivery system on neurodevelopmental and cognitive outcomes in adolescents with type 1 diabetes
Reiss AL, Jo B, Arbelaez AM, Tsalikian E, Buckingham B, Weinzimer SA, Fox LA, Cato A, White NH, Tansey M, Aye T, Tamborlane W, Englert K, Lum J, Mazaika P, Foland-Ross L, Marzelli M, Mauras N. A Pilot randomized trial to examine effects of a hybrid closed-loop insulin delivery system on neurodevelopmental and cognitive outcomes in adolescents with type 1 diabetes. Nature Communications 2022, 13: 4940. PMID: 36042217, PMCID: PMC9427757, DOI: 10.1038/s41467-022-32289-x.Peer-Reviewed Original ResearchConceptsHybrid closed-loop insulin delivery systemStandard care groupType 1 diabetesClosed-loop insulin delivery systemWhite matter volumeCare groupPrimary outcomeInsulin delivery systemsMatter volumeFractional anisotropyCognitive AssessmentRigorous glucose controlDiagnosis of T1DClosed-loop groupBetter diabetes controlDiabetes care groupsConcept pilot studyYears of ageAcademic medical centerFunctional brain activityCortical surface areaMonths study durationRandomized participantsDiabetes controlGlucose controlContinuous Glucose Monitoring in Adults With Type 1 Diabetes With 35 Years Duration From the DCCT/EDIC Study.
Gubitosi-Klug RA, Braffett BH, Bebu I, Johnson ML, Farrell K, Kenny D, Trapani VR, Meadema-Mayer L, Soliman EZ, Pop-Busui R, Lachin JM, Bergenstal RM, Tamborlane WV. Continuous Glucose Monitoring in Adults With Type 1 Diabetes With 35 Years Duration From the DCCT/EDIC Study. Diabetes Care 2022, 45: 659-665. PMID: 35076697, PMCID: PMC8918229, DOI: 10.2337/dc21-0629.Peer-Reviewed Original ResearchConceptsType 1 diabetesContinuous glucose monitoringInsulin pumpDCCT/EDIC studyComplications Trial/EpidemiologyGlucose monitoringPercent timeRelevant clinical goalsYears of ageMean sensor glucoseSubset of adultsComplications StudyEDIC studyEntire recording periodOlder patientsGlycemic excursionsDiabetes controlSignificant hypoglycemiaDiabetes InterventionsYears durationHypoglycemiaSensor glucoseClinical goalsHyperglycemic excursionsType 1
2021
Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study.
Mauras N, Buckingham B, White NH, Tsalikian E, Weinzimer SA, Jo B, Cato A, Fox LA, Aye T, Arbelaez AM, Hershey T, Tansey M, Tamborlane W, Foland-Ross LC, Shen H, Englert K, Mazaika P, Marzelli M, Reiss AL. Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study. Diabetes Care 2021, 44: 983-992. PMID: 33568403, PMCID: PMC7985430, DOI: 10.2337/dc20-2125.Peer-Reviewed Original ResearchConceptsType 1 diabetesBrain volumeControl subjectsTotal brain volume differencesEarly-onset type 1 diabetesAge-matched control subjectsIntelligence quotientCognitive scoresWhite matter volumeBrain volume differencesContinuous glucose monitoringDiabetes groupFull-scale intelligence quotientDiabetes complicationsDiabetes controlTotal brainVerbal intelligence quotientDiabetesMatter volumeSensor glucoseCognitive testingGlucose monitoringMixed-effects modelsBrainGroup differences
2020
Refractive Error and Retinopathy Outcomes in Type 1 Diabetes The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
Hainsworth DP, Gao X, Bebu I, Das A, de Koo L, Barkmeier AJ, Tamborlane W, Lachin JM, Aiello LP, Group D. Refractive Error and Retinopathy Outcomes in Type 1 Diabetes The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Ophthalmology 2020, 128: 554-560. PMID: 32941962, PMCID: PMC7956062, DOI: 10.1016/j.ophtha.2020.09.014.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaDiabetic retinopathyRefractive errorProliferative DRMacular edemaDiabetes controlDiabetes InterventionsRisk factorsUnadjusted modelsComplications Trial/EpidemiologyStages of DRCox proportional hazards modelDCCT treatment groupEDIC years 4Refractive error statusStandard fundus photographsAlbumin excretion rateDuration of diabetesIndependent risk factorDCCT/EDICDiastolic blood pressureSignificant macular edemaProliferative diabetic retinopathyPotential risk factorsProportional hazards model
2019
Screening eye exams in youth with type 1 diabetes under 18 years of age: Once may be enough?
Gubitosi‐Klug R, Bebu I, White NH, Malone J, Miller R, Lorenzi GM, Hainsworth DP, Trapani VR, Lachin JM, Tamborlane WV, Group* F. Screening eye exams in youth with type 1 diabetes under 18 years of age: Once may be enough? Pediatric Diabetes 2019, 20: 743-749. PMID: 31206973, PMCID: PMC7217664, DOI: 10.1111/pedi.12877.Peer-Reviewed Original ResearchConceptsYears of ageType 1 diabetesDiabetic retinopathyEye examEarly Treatment Diabetic Retinopathy Study (ETDRS) scaleMild non-proliferative diabetic retinopathyDiabetic Retinopathy Study scaleNon-proliferative diabetic retinopathyDiabetic retinopathy assessmentDiabetic retinopathy statusBaseline glycated hemoglobinClinical trial evidenceSignificant macular edemaProliferative diabetic retinopathyStandardized clinical trialsDiabetic retinopathy examinationsRetinopathy assessmentRetinopathy statusBaseline characteristicsComplications TrialMacular edemaCase seriesDiabetes controlIncident casesTrial evidenceRisk Factors for Kidney Disease in Type 1 Diabetes
Perkins BA, Bebu I, de Boer IH, Molitch M, Tamborlane W, Lorenzi G, Herman W, White NH, Pop-Busui R, Paterson AD, Orchard T, Cowie C, Lachin JM, Group O. Risk Factors for Kidney Disease in Type 1 Diabetes. Diabetes Care 2019, 42: dc182062. PMID: 30833370, PMCID: PMC6489116, DOI: 10.2337/dc18-2062.Peer-Reviewed Original ResearchConceptsHigher systolic blood pressureHigher mean triglyceridesSystolic blood pressureRisk factorsKidney diseaseBlood pressureIncident macroalbuminuriaMean triglyceridesMultivariable Cox proportional hazards modelsGlomerular filtration rate lossCox proportional hazards modelComplications Trial (DCCT) cohortNonglycemic risk factorsModifiable risk factorsFrequency of screeningAssociation of baselineType 1 diabetesProportional hazards modelGlycemic exposureTrial cohortDiabetes controlMale sexHazards modelClinical strategiesAdvanced stage
2017
The Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study
Gubitosi-Klug RA, Braffett BH, White NH, Sherwin RS, Service FJ, Lachin JM, Tamborlane WV, Group T. The Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2017, 40: dc162723. PMID: 28550194, PMCID: PMC5521975, DOI: 10.2337/dc16-2723.Peer-Reviewed Original ResearchConceptsSevere hypoglycemiaTreatment groupsMean HbADiabetes therapyDCCT/EDIC cohortDCCT/EDIC studyIntensive diabetes therapyIntensive treatment groupSevere hypoglycemia ratesConventional treatment groupDuration of diabetesConventional diabetes therapyType 1 diabetesComplications (DCCT/EDIC) cohortEDIC studySimilar HbAComplications TrialHypoglycemia ratesLower HbADiabetes controlDCCT studyRisk factorsRelative riskHypoglycemiaLower risk
2015
Combining glucose monitoring and insulin delivery into a single device: current progress and ongoing challenges of the artificial pancreas
Ang KH, Tamborlane WV, Weinzimer SA. Combining glucose monitoring and insulin delivery into a single device: current progress and ongoing challenges of the artificial pancreas. Expert Opinion On Drug Delivery 2015, 12: 1579-1582. PMID: 26389567, PMCID: PMC4837694, DOI: 10.1517/17425247.2015.1074174.Peer-Reviewed Original ResearchConceptsBurden of careGlucose monitoringInsulin deliveryMultiple hormone systemsOverall glucose levelsType 1 diabetesContinuous glucose monitoringGlycemic targetsSevere hypoglycemiaDiabetes controlInsulin delivery systemsInpatient settingGlucose levelsPharmacokinetic profileOutpatient environmentInsulin analoguesPump suspensionInsulin pumpHypoglycemiaPsychosocial tollHormone systemTarget rangeArtificial pancreasPreliminary findingsCare
2012
The Landmark JDRF Continuous Glucose Monitoring Randomized Trials: a Look Back at the Accumulated Evidence
Ruedy KJ, Tamborlane WV, for the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The Landmark JDRF Continuous Glucose Monitoring Randomized Trials: a Look Back at the Accumulated Evidence. Journal Of Cardiovascular Translational Research 2012, 5: 380-387. PMID: 22538483, DOI: 10.1007/s12265-012-9364-9.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBiomarkersBlood GlucoseBlood Glucose Self-MonitoringChildDiabetes Mellitus, Type 1Equipment DesignEvidence-Based MedicineGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsMulticenter Studies as TopicPatient SatisfactionPredictive Value of TestsRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsContinuous glucose monitorRandomized trialsT1D managementMulticenter Randomized TrialType 1 diabetesStandard glucose monitoringPrimary studiesComplications TrialSevere hypoglycemiaHemoglobin levelsDiabetes controlBiochemical hypoglycemiaCGM usePatientsGlucose monitoringAccumulated evidenceSecondary studiesReduced exposureTrialsA1CHypoglycemiaGlucose monitorSubjectsDCCTDiabetes
2010
Effect of Prior Intensive Therapy in Type 1 Diabetes on 10-Year Progression of Retinopathy in the DCCT/EDIC: Comparison of Adults and Adolescents
White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP, Davis MD, . Effect of Prior Intensive Therapy in Type 1 Diabetes on 10-Year Progression of Retinopathy in the DCCT/EDIC: Comparison of Adults and Adolescents. Diabetes 2010, 59: 1244-1253. PMID: 20150283, PMCID: PMC2857905, DOI: 10.2337/db09-1216.Peer-Reviewed Original ResearchConceptsEDIC year 10Beneficial effectsPrior glycemic controlPrior intensive therapyProgression of retinopathyDCCT/EDICYear 10Type 1 diabetesComplications StudyDCCT closeoutMean A1CComplications TrialA1c levelsGlycemic controlIntensive therapySevere hypoglycemiaDiabetes controlINT groupDiabetes InterventionsDiabetic retinopathyCON groupSlow progressionConventional groupFormer adolescentsComparison of adult
2008
Past, present, and future of insulin pump therapy: better shot at diabetes control
Sherr J, Tamborlane WV. Past, present, and future of insulin pump therapy: better shot at diabetes control. Annals Of Global Health 2008, 75: 352-361. PMID: 18729180, PMCID: PMC2562271, DOI: 10.1002/msj.20055.Peer-Reviewed Original ResearchConceptsPump therapyDiabetes controlContinuous subcutaneous insulin infusion (CSII) therapySubcutaneous insulin infusion therapyContinuous subcutaneous insulin infusionInsulin pump therapyInsulin infusion therapySubcutaneous insulin infusionType 1 diabetesComplications TrialInfusion therapyInsulin infusionIntensive treatmentPump useTherapyArtificial pancreasContinuous glucose sensorsDelivery systemFindingsSelection criteriaPatientsDiabetesInfusionPancreasNew findings
2007
The transition to young adulthood in youth with type 1 diabetes on intensive treatment
Insabella G, Grey M, Knafl G, Tamborlane W. The transition to young adulthood in youth with type 1 diabetes on intensive treatment. Pediatric Diabetes 2007, 8: 228-234. PMID: 17659065, DOI: 10.1111/j.1399-5448.2007.00266.x.Peer-Reviewed Original ResearchConceptsQuality of lifeDepressive symptomsYoung adulthoodIntensive treatmentPsychosocial outcomesDisease-related worriesPediatric diabetes clinicType 1 diabetesChart reviewComplications TrialDiabetes clinicIntensive therapyDiabetes complicationsDiabetes controlTreatment groupsSuch symptomsMetabolic controlIntervention studiesSymptomsDiabetesYoung adultsEarly adulthoodLonger durationHigh levelsAdulthood
2006
Optimal control of type 1 diabetes mellitus in youth receiving intensive treatment
Springer D, Dziura J, Tamborlane WV, Steffen AT, Ahern JH, Vincent M, Weinzimer SA. Optimal control of type 1 diabetes mellitus in youth receiving intensive treatment. The Journal Of Pediatrics 2006, 149: 227-232. PMID: 16887440, DOI: 10.1016/j.jpeds.2006.03.052.Peer-Reviewed Original ResearchConceptsType 1 diabetes mellitusRace/ethnicityLow socioeconomic statusSocioeconomic statusDiabetes mellitusLarge clinical practiceDuration of diabetesOptimal glycemic controlBody mass indexPoor metabolic controlAge 18 yearsGlycemic targetsInjection therapyGlycemic controlDiabetes controlMass indexFemale sexDatabase reviewInsulin administrationIntensive treatmentMonths durationTrial recommendationsMultiple linear regression analysisTherapeutic goalsClinical practiceFulfilling the promise of insulin pump therapy in childhood diabetes
Tamborlane WV. Fulfilling the promise of insulin pump therapy in childhood diabetes. Pediatric Diabetes 2006, 7: 4-10. PMID: 16774611, DOI: 10.1111/j.1399-543x.2006.00171.x.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoring systemContinuous subcutaneous insulin infusion (CSII) treatmentType 1 diabetes mellitusRapid-acting insulin analoguesTreatment of T1DMComplications TrialDiabetes mellitusDiabetes controlGlucose monitoring systemChildhood diabetesFavorable outcomeInsulin analoguesInfusion treatmentInsulin pumpTherapyMinimal riskT1DMDiabetesInsulinTreatmentMellitusHypoglycemiaCSIIRecent introduction
2005
Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a Diabetes Research in Children Network (DirecNet) Study
Tamborlane WV, Kollman C, Steffes MW, Ruedy KJ, Dongyuan X, Beck RW, Chase P, Fox LA, Wilson DM, Tsalikian E. Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a Diabetes Research in Children Network (DirecNet) Study. Pediatric Diabetes 2005, 6: 13-16. PMID: 15787896, DOI: 10.1111/j.1399-543x.2005.00088.x.Peer-Reviewed Original ResearchConceptsDCA 2000Central laboratory valuesHbA1c valuesClinical centersLaboratory valuesComplications Trial/EpidemiologyType 1 diabetes mellitusMean differenceDiabetes researchBaseline HbA1c levelsHemoglobin A1c levelsCentral laboratoryOutpatient clinical trialAdditional blood samplesCentral laboratory methodHbA1c levelsA1c levelsDiabetes mellitusDiabetes practiceDiabetes controlDiabetes InterventionsClinical trialsSame visitBlood samplesReference standard
2002
Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups
Ahern JA, Boland EA, Doane R, Ahern JJ, Rose P, Vincent M, Tamborlane WV. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatric Diabetes 2002, 3: 10-15. PMID: 15016169, DOI: 10.1034/j.1399-5448.2002.30103.x.Peer-Reviewed Original ResearchDiabetes programContinuous subcutaneous insulin infusion (CSII) therapySubcutaneous insulin infusion therapyDiabetes-related adverse eventsDaily insulin dosesMean HbA1c levelPrimary efficacy outcomeSevere hypoglycemic eventsPatients 18 monthsPrimary safety measureInsulin infusion therapyYr of ageEfficacy outcomesHbA1c levelsAdverse eventsInjection therapyYounger patientsPump treatmentDiabetes controlHypoglycemic eventsInsulin dosesInfusion therapyTherapeutic alternativeClinic settingClinical data